Management of Renal Artery Stenosis Kent MacKenzie, MD Division of Vascular Surgery McGill University Montreal, Quebec.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.
RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Harvard Medical School Duane S. Pinto, M.D. Director Peripheral Angiographic Core Laboratory, TIMI Data Coordinating Center Director, Cardiology Fellowship.
National Institute for Health and Clinical Excellence.
The DRASTIC Trial. Dutch Renal Artery Stenosis Intervention Cooperative Reference van Jaarsveld BC, Krijnen P, Derkx FHM, et al. Resistance to antihypertensive.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis NEJM, Jan 2014, M Graham-Brown 28/05/14.
Zehra Eren, M.D.. explain hypertansion and renal disease interaction, describe renovascular diseases describe diagnostic evaluation explan therapy in.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
Controversies in renal arterial interventions. ACHILLES CHATZIIOANNOU, MD Assoc. Professor of Radiology American Board of Radiology.
New guidelines for CABG
Renovascular Hypertension S M Reza Khatami MD Associate professor Tehran University of Medical Sciences Tehran 1392.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
What Is Peripheral Vascular Disease? Daniel B. Walsh, M.D. Professor of Surgery, Section of Vascular Surgery Vice-Chair, Department of Sugery Dartmouth-Hitchcock.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Renovascular Disease Daniel Shoskes MD, MSc, FRCSC Professor of Surgery/Urology Glickman Urological and Kidney Institute Cleveland Clinic.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
Renal Artery Stenosis November 12, 2009 Lance D. Dworkin, M.D., and Christopher J. Cooper, M.D. Clinical Practice 2010 년 3 월 23 일 화요일 신장내과 R4 이완수.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Hypertension and renovascular hypertension BY Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Renovascular hypertension Dr Saad Al Shohaib KAUH.
BY Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Relationship between coronary and renal artery disease and associated risk factors in hypertensive and diabetic patients undergoing coronary angiography.
KIDNEY & HYPERTENTION 1 Dr. Ruba Nashawati. Kidney Hypertension 2.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
The STAR Study. Cardiovascular Disease Antihypertensives The STAR Study Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis and Impaired.
Faramarz Amiri MD IUMS.  Severe carotid disease (defined as >80%) 8–12%  Severe carotid disease (>70%) in those with three vessel or left main coronary.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Uncertain Value of Renal Artery Interventions:
Renal vascular disease
Management of Hypertension according to JNC 7
Renovascular Disease Daniel Shoskes MD, MSc, FRCSC
Renal Artery Angioplasty and Stenting: Optimal Patient Selection
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
TUCOM Internal Medicine 4th class
Carotid Artery Stenosis
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
Renal Artery Angioplasty and Stenting
Patient Selection Indications for Renal Intervention
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
The Role of Interventional Treatment for The Failing Grafts
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
The Anglo Scandinavian Cardiac Outcomes Trial
RAAS Blockade: Focus on ACEI
Systolic Blood Pressure Intervention Trial (SPRINT)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Correlation between endothelial function and hypertension
These slides highlight a report from a Hotline Session and a Satellite symposium held at the European Society of Cardiology Congress, 2003 in Vienna Austria,
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Management of Renal Artery Stenosis Kent MacKenzie, MD Division of Vascular Surgery McGill University Montreal, Quebec

Disclosures None

Atherosclerotic RAS Often orificial/ostial Associated aortic atherosclerosis Associated atherosclerosis elsewhere – Coronary – Carotid – Peripheral Fibrointimal Hyperplasia (FMD)

Atherosclerotic RAS Clinical Consequences – Hypertension – Ischemic nephropathy – Chronic renal failure – Dialysis

Hypertension

1.Picture Renin-AII-Ald

Angiotensin II Vasoconstriction Sodium Retention Aldosterone Release

Sustained HTN Adaptive changes  PVR Heart Arteries Endothelial dysfunction  Nitrous oxide

The presence of hypertension is considered a prerequisite for renal artery intervention.

Diagnosis of RAS Hemodynamically significant lesion in renal artery in a patient with HPTN – Pressure gradient Diagnosis depends on identifying: – a pressure gradient – surrogate of a pressure gradient Functional surrogate Imaging surrogate

Functional Studies Intravenous Pyelography Differential Renal Function Studies Plasma Renin Activity Simulated Plasma Renin Activity Renal Vein Renin Catpopril Renal Scintography

Functional Studies

Functional Studies - Screening

Imaging Diagnosis Imaging surrogates for hemodynamic RAS – Duplex ultrasound – CT – MRA – Angiography

CT Angio – Minimally invasive – Calcification artifact

MRA – NSF – ?overestimates – experience

Duplex Ultrasound – PSV criteria – PSV RA/Aorta ratios Picture

Angiography – ? Smaller contrast load – Allows intervention

Imaging Diagnosis of RAS

In Practice High likelihood of RAS Good clinical indications for intervention – Duplex ultrasound – Ad-hoc Diagnostic +/- Therapeutic renal arteriography

Indications for Revascularization The presence of hypertension is considered a prerequisite for renal artery intervention.

Revascularization Potential Indications for renal revascularization – Incidental, asymptomatic RAS with need for aortic reconstruction – RAS with renal dysfunction alone – RAS with hypertension – RAS with hyperpertension and renal dysfunction – RAS with angina – RAS with recurrent flash pulmonary edema Chronic HPTN issues Acute HPTN issues

Revascularization with aortic surgery (prophylactic) 69 y.o. patient requires: – Open AAA repair – Endo AAA repair – Aortofemoral bypass for occlusive dx. Incidental imaging finding of severe RAS No severe HPTN at diagnosis

Revascularization with aortic surgery (prophylactic) 100 hypothetical patients with unsuspected RAS who will undergo aortic surgery – 44% (44 patients) lesion progression and RVH 36% (16 patients) may develop preventable reduction in renal function 66% (11 patients) will demonstrate restored function with delayed renal treatment Hansen KJ et al

Revascularization with aortic surgery (prophylactic) Therefore only 5 patients (5%) will gain a unique benefit from prophylactic renal artery repair Risk of adverse event with combined aortic/renal revasc. – 5-6% mortality in the best hands – 3-4% late failure of operative repair Therefore, prophylactic renal revasc. will potentially result in benefit in 5% of patients yet an adverse outcome in 10% Hansen KJ et al

Revascularization with aortic surgery (prophylactic) Prophylactic renal revascularization alone or in conjunction with aortic reconstruction is therefore not indicated – Surgical reconstruction – Catheter-based reconstruction Hansen KJ et al

Renal Insufficiency and RAS The absence of hypertension in a patient with RAS and excretory dysfunction suggests the presence of severe parenchymal disease Without HPTN, response to revascularization is poor

RAS and Hypertension alone Treatment is empiric Expectation of clinical improvement is less Unilateral vs. Bilateral RAS Hypertension response is poorly predictable

Accumulated experience has resulted in a paradigm shift in approach to selecting patients for intervention Surgical literaturePTA RAS and severe HPTN as a pre-intervention predictor of response Changes in renal function post-intervention being the short-term outcome Improvements in all-cause cardiovascular outcomes being the outcome of interest in trials evaluating RA intervention Hypertension with Renal Insufficiency

All patients

Hypertension with Renal Insufficiency

Treatment of hemodynamically significant RAS in a patient with: – Hypertension (severe) – Rapidly progressive decline in renal function – Salvageable renal mass Surgical literature suggests expectation of improved BP control and reduction in rate of functional loss Hypertension with Renal Insufficiency

RAS with angina or pulm edema Acute myocardial strain Acute episodes of severe hypertension Multiple case-series suggesting significant stabilzation of cardiac status after renal revascularization

Surgical Revascularization – Renal/aortic endarterectomy – Renal artery bypass Direct – Aortorenal bypass, iliorenal bypass – Renal artery reimplantation Indirect – Hepatorenal bypass – Splenorenal bypass – Mesorenal bypass Options for Intervention

Surgical Revascularization – Ex-vivo reconstruction To be considered in: – Solitary kidney – Complex renal artery branch reconstructions Options for Intervention

Percutaneous Treatment – Renal artery angioplasty – Renal artery angioplasty with provisional/selective stenting – Renal artery stenting Options for Intervention

No controlled studies comparing angioplasty vs. stenting Limited data comparing angioplasty/stenting to surgical revascularization No strong evidence demonstrating superiority of surgical revascularization over medical therapy No strong evidence demonstrating superiority of renal angioplasty/stenting over medical therapy Uncontrolled, non-randomized data supports the use of renal revascularization in high-risk groups

Side-by-side comparison of large surgical series and renal angioplasty series suggests better durability and improvements in renal insufficiency in surgical patients Comes at the cost of higher peri-procedural morbidity and mortality So percutaneous treatments selected in most patients other than those with need for aortic reconstruction or with contraindications for PTA

Randomized Trials Percutaneous Renal Artery Intervention

EMMA Trial, 1998 Unilateral atherosclerotic RAS Normal renal function 59 patients randomized Primary outcomes – Ambulatory blood pressure (ABP) Secondary outcomes – Treatment score – Complications

No difference in ABP But lower Treatment Score (fewer meds) in angioplasty group Higher procedural complication in angioplasty group (26% vs. 8%) Criticisms: – 1/3 eligible screened patients not enrolled because of patient or physician preference for angioplasty – Protocol called for antihypertensives in angioplasty group if BP control ‘not optimal’ Study design biased to not demonstrate primary outcome

Scottish/Newcastle study, 1998 Atherosclerotic uni- or bilat- RAS 135 patients eligible – Only 54 randomized – Non-randomized patients included for analysis Primary endpoints – Mean BP and serum creatinine 4 weeks and 6 months

Mean BP improved in medical and intervention arms during study period Mean BP after angioplasty improved only in the bilateral, randomized group Reduced hypertensive medication usage from 2.8 to 2.3 drugs in angioplasty groups No differences in renal function between groups

DUTCH renal angioplasty trial, patients with atherosclerotic RAS randomized Inclusion: – RAS >50% Diast. BP >95 mm Hg Worsening Creat on ACE inhibitor Primary Endpoints – Systolic and diastolic BP at 3 and 12 months Secondary Endpoints – Number of antihypertensive medications

RESULTS Blood pressure no different between groups Number of drugs in angioplasty group diminished (1.9 vs. 2.5) Criticisms: – Study design aimed for diastolic BP 95 mmHg Keeping drug numbers same might have led to improved BP in angioplasty group – 50% of patients in medical arm crossed over to angioplasty within 3 months of randomization

The Big Hurt

Patients where role of angioplasty was unclear BP was not severe (2 meds, mean 149/76) 40% patients had stenosis <70% Primary end-point decline in renal function 25% had normal renal function Only 12% had recent rapid decline in fcn.

Patients excluded were those most likely to gain benefit – Patients with: High-grade stenosis Poorly controlled hypertension Rapidly declining renal function Likely significant selection bias based on lack of equipoise to randomize patients

Also identified: – 27% of patient in the medical arm had an improvement of more than 10  mol/L during the period of study – This finding helps explain in part, the results of revascularization in uncontrolled, non-randomized cohort studies of renal angioplasty and surgical revascularization

The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) Study: Rationale and Methods Timothy P. Murphy, MD, Christopher J. Cooper, MD, Lance D. Dworkin, MD, William L. Henrich, MD, John H. Rundback, MD, Alan H. Matsumoto, MD, Kenneth A. Jamerson, MD, Ralph B. D'Agostino, PhD

Still not in publication

Treatment Recommendations Medical Therapy

Treatment Recommendations Interventional Therapy

Treatment Recommendations Interventional Therapy

Treatment Recommendations Interventional Therapy

Treatment Recommendations Interventional Therapy

Treatment Recommendations Interventional Therapy

Treatment Recommendations Surgical Therapy

Treatment Recommendations Surgical Therapy

Summary Renal Revascularization Sound concept to treat a serious problem Basic science observations and observational studies support its role in treating RAS

Intervention – Severe bilateral RAS with severe hypertension – Selected unilateral severe RAS with severe hypertension – Severe RAS with renal dysfunction and HPTN If rapid progressive over short period – RAS with angina Associated with severe hypertension – RAS with CHF Coexistent hypertension, flash pulmonary edema

Angioplasty/Stent – First-line of intervention in the majority of cases Reduced procedural morbidity and mortality – Magnitude of benefit and durability – More evidence is required

Surgical Reconstruction Indication for renal revascularization and concomitant indication for aortic reconstruction – Aneurysm – Occlusive disease Renal occlusive disease involving aorta or renal artery bifurcation/branches Concomitant renal artery/branch aneurysm Young patient with good operative risk

Thank You